Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
11-Mar-2026 | 5,662 | 5,665 | 5,514.5 | 5,544.5 | 19,474 | 82,43,19,503.5 | 85,408 |
12-Mar-2026 | 5,515.5 | 5,528 | 5,400 | 5,444 | 17,850 | 66,49,47,280 | 67,357 |
13-Mar-2026 | 5,422 | 5,471.5 | 5,335.5 | 5,355.5 | 16,686 | 55,67,53,807 | 56,498 |
16-Mar-2026 | 5,393 | 5,407 | 5,233 | 5,323 | 21,767 | 1,08,42,58,559.5 | 1,31,678 |
17-Mar-2026 | 5,317 | 5,350 | 5,285 | 5,333.5 | 15,674 | 67,74,40,520.5 | 77,584 |
18-Mar-2026 | 5,335 | 5,423 | 5,315 | 5,351.5 | 18,597 | 35,12,17,645 | 35,775 |
19-Mar-2026 | 5,309 | 5,336 | 5,222.5 | 5,240 | 14,132 | 31,52,00,265.5 | 27,130 |
20-Mar-2026 | 5,245 | 5,298.5 | 5,211 | 5,257.5 | 20,696 | 1,71,17,85,107 | 2,17,535 |
23-Mar-2026 | 5,260 | 5,272.5 | 5,111.5 | 5,144.5 | 23,945 | 57,00,59,056.5 | 49,986 |
24-Mar-2026 | 5,200 | 5,304.5 | 5,160.5 | 5,297 | 14,266 | 41,50,56,209 | 37,565 |
25-Mar-2026 | 5,355 | 5,464 | 5,311.5 | 5,435.5 | 11,503 | 33,19,96,198 | 33,315 |
27-Mar-2026 | 5,401 | 5,419.5 | 5,259 | 5,344.5 | 27,004 | 77,70,98,314.5 | 86,631 |
30-Mar-2026 | 5,291 | 5,345.5 | 5,252 | 5,299 | 22,086 | 96,82,08,855.5 | 97,974 |
01-Apr-2026 | 5,320.5 | 5,454 | 5,210 | 5,244.5 | 26,029 | 62,92,49,813 | 55,670 |
02-Apr-2026 | 5,210.5 | 5,276.5 | 5,075 | 5,258 | 16,161 | 36,28,62,743 | 23,841 |
06-Apr-2026 | 5,273.5 | 5,305.5 | 5,155 | 5,236.5 | 15,136 | 42,46,11,843 | 37,400 |
07-Apr-2026 | 5,236.5 | 5,246.5 | 5,142 | 5,172.5 | 24,301 | 70,80,02,283.5 | 64,754 |
08-Apr-2026 | 5,278 | 5,295.5 | 5,214.5 | 5,246 | 26,516 | 76,52,79,141.5 | 78,394 |
09-Apr-2026 | 5,269 | 5,386.5 | 5,181.5 | 5,370.5 | 22,048 | 68,02,35,694 | 66,761 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
